Markus Puusepp appointed Chief Growth Officer
SHL Medical, a world-leading provider of advanced drug delivery solutions, is pleased to announce the appointment of Markus Puusepp as Chief Growth Officer (CGO). As CGO, Puusepp will be responsible for accelerating the company’s growth with a focus on innovation and customer experience.
Puusepp, who initially joined SHL Medical in 2017 as Director of Corporate Ventures, has played a pivotal role in shaping the company’s strategic vision as the Chief Strategy Officer (CSO) since 2020. In his new position, Puusepp will lead SHL Medical’s commercial strategic direction with a primary focus on developing cutting-edge customer services and solutions. These advancements aim to revolutionize the customer experience and strengthen the company’s competitive advantage.
“We are thrilled to have Markus Puusepp assume the role of Chief Growth Officer at SHL Medical,” said SHL Medical CEO Ulrich Faessler. “With his proven track record and deep understanding of our business, Markus is the ideal person to lead our global growth organization.”
“This is an exciting time for our company, as we navigate through remarkable growth and explore new markets,” said Puusepp. “I am committed to leveraging our expertise and collaborating with our talented teams to solidify our position as a global leader in drug delivery solutions.”
Puusepp’s appointment arrives at a crucial juncture in SHL Medical’s evolution, marked by significant growth in sales and production expansion as well as the emergence of new customer segments in the biopharmaceutical industry. The company is also venturing into new markets, making the addition of the Chief Growth Officer essential. The creation of this pivotal role not only highlights SHL Medical’s dedication to driving growth, but also reaffirms the company’s steadfast commitment to placing our customers at the forefront of our endeavors.
